title: The effect of an aldose reductase inhibitor on lens phosphorylcholine under hyperglycemic conditions: biochemical and NMR studies.
abstract: Phosphorylcholine (P-choline) is a precursor of the phospholipids in the lens membrane. A human lens normally contains approx. 1 mM P-choline but this is significantly lowered in some cataractous lenses. A normal rat lens contains a very high concentration (11 mM). We found that rat lens P-choline was depleted drastically when the lenses were exposed to hyperglycemic conditions either in culture, with galactose or xylose, or in vivo by streptozotocin-induced diabetes. The lens P-choline level was measured by fractionating the organic phosphates in the lens homogenate using an ion exchange column, or by quantitating the P-choline 31P NMR intensity in intact lenses. The results of both the chemical method and the noninvasive method agreed remarkably well. Besides the change in P-choline, the choline influx was also drastically reduced both in lenses from diabetic rats and in lenses incubated with 30 mM xylose. In addition, the ATP concentration was greatly diminished under similar conditions. The changes in P-choline, choline, and ATP could all be prevented in the presence of an aldose reductase inhibitor (ARI). It is thus concluded that these changes in phospholipid precursors may result from lenticular membrane defects caused by hyperglycemic stress. The effect of the lowered precursors on lipid biosynthesis was observed, and surprisingly showed a more rapid phospholipid-biosynthesis in the 2-week diabetic rat lens than in the 3-day diabetic rat lens.
authors.affiliation: Alcon Laboratories, Fort Worth, Texas 76115.
authors.forename: M F
authors.initials: MF
authors.lastname: Lou
authors.forename: R
authors.initials: R
authors.lastname: Garadi
authors.forename: D M
authors.initials: DM
authors.lastname: Thomas
authors.forename: P P
authors.initials: PP
authors.lastname: Mahendroo
authors.forename: B M
authors.initials: BM
authors.lastname: York
authors.forename: H M
authors.initials: HM
authors.lastname: Jernigan
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002794:Choline / Q000031:analogs & derivatives* / Q000378:metabolism; D003470:Culture Media; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005690:Galactose / Q000494:pharmacology; D007908:Lens, Crystalline / Q000378:metabolism*; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008563:Membrane Lipids / Q000096:biosynthesis; D009924:Organ Culture Techniques; D010767:Phosphorylcholine / Q000378:metabolism*; D051381:Rats; D011919:Rats, Inbred Strains; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*; D014994:Xylose / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D003470:Culture Media; D008563:Membrane Lipids; D010767:Phosphorylcholine; D000255:Adenosine Triphosphate; D014994:Xylose; D013401:Sugar Alcohol Dehydrogenases; D000449:Aldehyde Reductase; D002794:Choline; D005690:Galactose